ورود
مقالات فارسیISIکنفرانسهاژورنالها

COVID-۱۹ therapy approaches and vaccine development: the role of nanotechnology

محل انتشار: مجله علوم نانو، دوره: 8، شماره: 2
سال انتشار: 1400
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 321

فایل این مقاله در 9 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:
https://civilica.com/doc/1186834

شناسه ملی سند علمی:

JR_NAMJ-8-2_001

تاریخ نمایه سازی: 6 اردیبهشت 1400

چکیده مقاله:

Severe acute respiratory syndrome coronavirus ۲ (SARS-COV-۲) caused an outbreak in Wuhan, China in December ۲۰۱۹, and right after that SARS-COV-۲ spreads around the world infecting millions of people worldwide. This virus belongs to wide range virus family and cause moderate to severe signs in patients, the Sars-COV-۲, can spread faster than others between humans and leads to severe outbreak. Recently researchers succeed to develop various vaccines including inactivated or attenuated viral vaccines as well as subunit vaccines to prevent SARS-COV-۲ infection. Nanotechnology is advantageous for the design of vaccines since nano scale materials could benefit the delivery of antigens, and could be used as adjuvants to potentiate the response to the vaccines. Indeed, among various vaccines entered clinical trials, there are mRNA-based vaccine designed based on lipid nanoparticles. Herein, we summarized SARS-COV-۲ structure, pathogenesis, therapeutic approaches and some COVID-۱۹ vaccine candidates and highlighted the role of nanotechnology in developing vaccines against SARS-Cov-۲ virus.

کلیدواژه ها:

RNA ، Nanoparticle ، SARS-CoV-۲ ، Vaccine ، Therapy

نویسندگان

Maham Doagooyan

Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Seyedeh Hoda Alavizadeh

Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Seyed Mohammad Gheibihayat

Department of Medical Genetics, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Service, Yazd, Iran

Arad Boustan

Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Fatemeh Gheybi

Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • 1.Le TT, Andreadakis Z, Kumar A, Roman RG, Tollefsen S, ...
  • 2.Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 ...
  • 3.Eurosurveillance Editorial T. Updated rapid risk assessment from ECDC on ...
  • 4.Kahn JS, McIntosh K. History and recent advances in coronavirus ...
  • 5.Li Q, Guan X, Wu P, Wang X, Zhou L, ...
  • 6.Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 ...
  • 7.Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020; ...
  • 8.Lancet T. Global governance for COVID-19 vaccines. Lancet (London, England). ...
  • 9.Seah I, Agrawal R. Can the Coronavirus Disease 2019 (COVID-19) ...
  • 10.Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their ...
  • 11.Elfiky AA, Mahdy SM, Elshemey WM. Quantitative structure‐activity relationship and ...
  • 12.Hemida MG, Alnaeem A. Some one health based control strategies ...
  • 13.Báez-Santos YM, Mielech AM, Deng X, Baker S, Mesecar AD. ...
  • 14.Organization WH. Clinical management of severe acute respiratory infection when ...
  • 15.Ibrahim IM, Abdelmalek DH, Elshahat ME, Elfiky AA. COVID-19 spike-host ...
  • 16.Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, ...
  • 17.King AM, Lefkowitz E, Adams MJ, Carstens EB. Virus taxonomy: ...
  • 18.Lefkowitz EJ, Dempsey DM, Hendrickson RC, Orton RJ, Siddell SG, ...
  • 19.De Haan CA, Kuo L, Masters PS, Vennema H, Rottier ...
  • 20.Woo PC, Huang Y, Lau SK, Yuen K-Y. Coronavirus genomics ...
  • 21.Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of ...
  • 22.Ibrahim IM, Abdelmalek DH, Elfiky AA. GRP78: A cell’s response ...
  • 23.Lee AS. The ER chaperone and signaling regulator GRP78/BiP as ...
  • 24.Li J, Lee AS. Stress induction of GRP78/BiP and its ...
  • 25.Quinones QJ, Ridder GGd, Pizzo SV. GRP78, a chaperone with ...
  • 26.Rao RV, Peel A, Logvinova A, del Rio G, Hermel ...
  • 27.Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, ...
  • 28.Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, ...
  • 29.Li F. Structure, function, and evolution of coronavirus spike proteins. ...
  • 30.Sola I, Almazan F, Zuniga S, Enjuanes L. Continuous and ...
  • 31.Jin Y, Yang H, Ji W, Wu W, Chen S, ...
  • 32.Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, ...
  • 33.Wang M, Cao R, Zhang L, Yang X, Liu J, ...
  • 34.McCreary EK, Angus DC. Efficacy of Remdesivir in COVID-19. Jama. ...
  • 35.Yoo J-H. Uncertainty about the Efficacy of Remdesivir on COVID-19. ...
  • 36.Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, ...
  • 37.Que T, Wong V, Yuen K. Treatment of severe acute ...
  • 38.Cao B, Wang Y, Wen D, Liu W, Wang J, ...
  • 39.Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to ...
  • 40.Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. ...
  • 41.Kalil AC. Treating COVID-19—off-label drug use, compassionate use, and randomized ...
  • 42.Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments ...
  • 43.Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, ...
  • 44.Soo Y, Cheng Y, Wong R, Hui D, Lee C, ...
  • 45.Wang L-s, Wang Y-r, Ye D-w, Liu Q-q. A review ...
  • 46.Yu M, Wu J, Shi J, Farokhzad OC. Nanotechnology for ...
  • 47.Li B, Zhang X, Dong Y. Nanoscale platforms for messenger ...
  • 48.Hirano T, Murakami M. COVID-19: A new virus, but a ...
  • 49.Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, ...
  • 50.Yang Y, Shen C, Li J, Yuan J, Wei J, ...
  • 51.Al-Lawati H, Aliabadi HM, Makhmalzadeh BS, Lavasanifar A. Nanomedicine for ...
  • 52.Abd Ellah NH, Gad SF, Muhammad K, E Batiha G, ...
  • 53.Wang D, Hu B, Hu C, Zhu F, Liu X, ...
  • 54.Zhu N, Zhang D, Wang W, Li X, Yang B, ...
  • 55.Graham BS. Rapid COVID-19 vaccine development. Science. 2020; 368(6494): 945-946. ...
  • 56.Wu SC. Progress and Concept for COVID‐19 Vaccine Development. Biotechnology ...
  • 57.Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a ...
  • 58.Zhu F-C, Li Y-H, Guan X-H, Hou L-H, Wang W-J, ...
  • 59.Mahase E. Covid-19: Moderna vaccine is nearly 95% effective, trial ...
  • 60.Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, ...
  • 61.van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham ...
  • 62.Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, ...
  • 63.Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, ...
  • 64.Sun W, Leist SR, McCroskery S, Liu Y, Slamanig S, ...
  • 65.Raska MaJT, J. Mestecky, et al. DNA Vaccines for the ...
  • 66.Li L, Petrovsky NJErov. Molecular mechanisms for enhanced DNA vaccine ...
  • 67.Kang TL, Chelliah S, Velappan RD, Kabir N, Mohamad J, ...
  • 68.Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, ...
  • 69.Yoon I-K, Kim JH. First clinical trial of a MERS ...
  • 70.Wang J, Peng Y, Xu H, Cui Z, Williams RO. ...
  • 71.Smith TR, Patel A, Ramos S, Elwood D, Zhu X, ...
  • 72.Zhang Y, Zeng G, Pan H, Li C, Hu Y, ...
  • 73.Cohen J. COVID-19 shot protects monkeys. Science. 2020;368(6490):456-457. ...
  • 74.Palacios R, Patiño EG, de Oliveira Piorelli R, Conde MTRP, ...
  • 75.Organization WH. DRAFT landscape of COVID-19 candidate vaccines. World. 2020. ...
  • 76.Poland EG, McGuire DK, Ratishvili T, Poland GA. The economics ...
  • 77.Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine ...
  • 78.Schwarzinger M, Watson V, Arwidson P, Alla F, Luchini S. ...
    • نمایش کامل مراجع